source
- FDA staff flag peptide conflict concerns and warn drug ad rule could curb advertisingFDA staff have raised internal concerns about potential conflicts of interest among experts who will sit on an upcoming advisory panel reviewing peptide therapies. The staff memo warns that undiscl…
- Eli Lilly to buy psychedelics biotech AtaiBeckley for $2.8 billion, adding late-stage depression drugEli Lilly announced it will acquire New York‑based biotech AtaiBeckley in a transaction valued at about $2.8 billion. The agreement sets the purchase price at $6.75 per share, a 26 % premium to At…BioPharma Dive · 29d agoDealPositive